日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

在接受自体移植后来那度胺维持治疗并达到完全缓解的多发性骨髓瘤患者中，通过 EuroFlow 新一代流式细胞术和新一代测序检测到的微小残留病灶的预后价值：一项前瞻性比较研究

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2025.287411
Yoroidaka, Takeshi; Takamatsu, Hiroyuki; Urushihara, Ryota; Itagaki, Mitsuhiro; Yoshihara, Satoshi; Sato, Kota; Takezako, Naoki; Ozaki, Shuji; Suzuki, Kazuhito; Kohno, Kentaro; Muta, Tsuyoshi; Matsumoto, Morio; Terasaki, Yasushi; Yamashita, Takeshi; Fuchida, Shin-Ichi; Sakamoto, Jun; Ishida, Tadao; Suzuki, Kenshi; Murakami, Hirokazu; Durie, Brian G M; Shimizu, Kazuyuki
多发性骨髓瘤
细胞生物学
FCM
骨髓瘤
发表日期：2025
文献求助 收藏

Lymphoid Proliferations and Lymphoma Associated with Immune Deficiency, and Dysregulation in a Patient Treated with Cyclosporine Monotherapy for Psoriasis

接受环孢素单药治疗银屑病的患者出现免疫缺陷和失调相关的淋巴组织增生和淋巴瘤

期刊:
影响因子:
doi:10.1007/s12288-024-01781-3
Nakanishi, Toshiyuki; Noto, Satoshi; Nakamichi, Yusuke; Nakai, Mori; Takezako, Naoki
银屑病
淋巴瘤
免疫/内分泌
发表日期：2025
文献求助 收藏

Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group

泛太平洋多发性骨髓瘤工作组关于复发/难治性多发性骨髓瘤临床实践中抗CD38疗法的共识指南和建议

期刊:Clinical Hematology International
影响因子:
doi:10.46989/001c.141401
Chen, Wenming; Cai, Zhen; Chim, Chor Sang; Chng, Wee Joo; Du, Juan; Fu, Chengcheng; Gao, Wen; Hanamura, Ichiro; Hou, Jian; Huang, Jeffrey Shang-Yi; Ishida, Tadao; Li, Chunrui; Liu, Aijun; Ptushkin, Vadim; Takezako, Naoki; Wong, Raymond Siu Ming; Yoon, Dok Hyun
多发性骨髓瘤
CD3
CD38
骨髓瘤
发表日期：2025
文献求助 收藏

Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group

CD38单克隆抗体四联疗法在初诊多发性骨髓瘤临床实践中的应用及管理共识指南和建议：来自泛太平洋多发性骨髓瘤工作组

期刊:Clinical Hematology International
影响因子:
doi:10.46989/001c.133682
Chen, Wenming; Cai, Zhen; Chim, James Cs; Chng, Wee Joo; Du, Juan; Fu, Chengcheng; Hanamura, Ichiro; Hou, Jian; Huang, Jeffrey Shang-Yi; Ishida, Tadao; Liu, Aijun; Ptushkin, Vadim; Semenova, Anastasiya; Takezako, Naoki; Wong, Raymond Siu Ming
单克隆抗体
多发性骨髓瘤
CD3
CD38
骨髓瘤
发表日期：2025
文献求助 收藏

Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma

自体 HSCT 联合新型药物诱导和巩固治疗，随后以来那度胺维持治疗，治疗未治疗的多发性骨髓瘤

期刊:Cancer Science
影响因子:4.5
doi:10.1111/cas.16158
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto; Japan Study Group for Cell Therapy and Transplantation
肿瘤
骨髓瘤
发表日期：2024
文献求助 收藏

NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With Elotuzumab, Lenalidomide Plus Dexamethasone

NK细胞和T淋巴细胞动力学可预测接受埃罗妥珠单抗、来那度胺联合地塞米松治疗的多发性骨髓瘤患者的预后

期刊:
影响因子:
doi:10.21873/cdp.10293
Suzuki, Kazuhito; Matsumoto, Morio; Hiramatsu, Yasushi; Takezako, Naoki; Tamai, Yotaro; Suzuki, Kenshi
多发性骨髓瘤
细胞生物学
骨髓瘤
发表日期：2024
文献求助 收藏

Corrigendum to "Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation": [Annals of Oncology 28 (2017):2503-2510]

对“基于测序的微小残留病灶检测在接受自体干细胞移植的多发性骨髓瘤患者中的预后价值”的更正：[肿瘤学年鉴 28 (2017):2503-2510]

期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2022.08.004
Takamatsu, H; Takezako, N; Zheng, J; Moorhead, M; Carlton, V E H; Kong, K A; Murata, R; Ito, S; Miyamoto, T; Yokoyama, K; Matsue, K; Sato, T; Kurokawa, T; Yagi, H; Terasaki, Y; Ohata, K; Matsumoto, M; Yoshida, T; Faham, M; Nakao, S
肿瘤
发育与干细胞
干细胞
肿瘤免疫
多发性骨髓瘤
骨髓瘤
细胞生物学
发表日期：2023
文献求助 收藏

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

埃洛妥珠单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤：来自随机 II 期 ELOQUENT-3 试验的最终总生存期分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.02815
Dimopoulos, Meletios A; Dytfeld, Dominik; Grosicki, Sebastian; Moreau, Philippe; Takezako, Naoki; Hori, Mitsuo; Leleu, Xavier; LeBlanc, Richard; Suzuki, Kenshi; Raab, Marc S; Richardson, Paul G; Popa McKiver, Mihaela; Jou, Ying-Ming; Yao, David; Das, Prianka; San-Miguel, Jesús
多发性骨髓瘤
NT-3
骨髓瘤
发表日期：2023
文献求助 收藏

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

伊沙佐米联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性（基于注射用蛋白酶体抑制剂治疗之后）

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-023-05212-7
Abe, Yu; Sasaki, Makoto; Takezako, Naoki; Ito, Shigeki; Suzuki, Kazuhito; Handa, Hiroshi; Chou, Takaaki; Yoshida, Takahiro; Mori, Ikuo; Shinozaki, Tomohiro; Suzuki, Kenshi
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

更正：伊沙佐米联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性（基于注射用吡咯烷酮类药物治疗之后）

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-023-05355-7
Abe, Yu; Sasaki, Makoto; Takezako, Naoki; Ito, Shigeki; Suzuki, Kazuhito; Handa, Hiroshi; Chou, Takaaki; Yoshida, Takahiro; Mori, Ikuo; Shinozaki, Tomohiro; Suzuki, Kenshi
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏